> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Fast Track for Elevation’s Seribantumab
- URL: https://www.fdaweb.com/fast-track-for-elevations-seribantumab/
- Published: 2022-05-25T12:00:00.000Z
- Updated: 2026-09-14T17:46:09.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5151900

FDA has granted fast track designation to Elevation Oncology’s seribantumab for the tumor-agnostic treatment of advanced solid tumors that harbor NRG1 gene fusions. The company [says](https://investors.elevationoncology.com/2022-05-25-Elevation-Oncology-Announces-FDA-Fast-Track-Designation-Granted-to-Seribantumab-for-the-Tumor-Agnostic-Treatment-of-Solid-Tumors-Harboring-NRG1-Gene-Fusions?ref=fdaweb.com) it is evaluating seribantumab in the Phase 2 CRESTONE study.